TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01504178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: administration during 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of duloxetine
Description: administration during 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of duloxetine
Description: administration during 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of apomorphine
Description: injection performed at D28

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: injection of apomorphine
Description: injection performed at D28

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: injection of placebo of apomorphine
Description: performed at D28
Study: NCT00738140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program
Description: 12-lesson program which will cover diet, exercise, and behavior modification.
Study: NCT01628159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix Drug Coated Balloon
Description: balloon angioplasty with a drug coated balloon
Study: NCT04110015

Intervention type: DEVICE
Intervention: virtual visual field
Description: Patients with identified conditions will be invited to do a virtual visual field test with virtual reality headsets.

Intervention type: DEVICE
Intervention: virtual visual field
Description: Patients with identified conditions will be invited to do a virtual visual field test with virtual reality headsets.
Study: NCT02686307

Intervention type: PROCEDURE
Intervention: ICD Implant
Description: Implantation of an implantable cardioverter/defibrillator
Study: NCT03877835

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripheral nerve blocks
Description: LSIB + SSNB
Study: NCT00634036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo (inert tablet)
Study: NCT06066268

Intervention type: DIAGNOSTIC_TEST
Intervention: Critical limb ischemia: analysis of RNAs
Description: analysis of miRNA expression levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Controls: analysis of RNAs
Description: analysis of miRNAs expression levels
Study: NCT01504178

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-Dopa
Description: performed at D28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of placebo of L-Dopa
Description: performed at D28

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: injection of placebo of L-Dopa
Description: performed at D28
Study: NCT03366727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-coated balloon catheter （Orchid, Acotec）
Description: After predilation, using drug-coated balloon catheter to cover the whole treated segment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: plain balloon catheter (Admiral, medtronic)
Description: After predilation, using plain balloon catheter to cover the whole treated segment
Study: NCT03177525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social SUCCESS
Description: Social SUCCESS will run for 12 weeks, with up to 5 children with ASD per group. Parents will attend didactic group sessions focused on motivating children with ASD to initiate to peers (90 min weekly) and will attend a portion of the existing 90 min social group to practice applying these strategies with their children and peer volunteers. Parent training will utilize the manual Improving Socialization in Individuals with Autism.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait List
Description: Participants assigned to the Wait List will continue stable community treatments for 12 weeks and will be provided an intervention similar to Social SUCCESS upon completion of all post measures.
Study: NCT03309137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine flush
Description: 1. For patients randomized to the CHG-LockTM device, attach a attach a BD Posiflush ™ 0.9% Sodium Chloride (Na Cl) 10ml syringe and a CHG-Lock™ device for each IV line that is to be locked. Follow hospital approved protocol for flush, volumes and hand hygiene.~   After a Catheter has been locked, before re-accessing the catheter for further sampling or infusions, all fluid should be aspirated from the catheter to clear the device of CHG, Heparin and the like. This should also confirm patency of the device.~2. Discard the syringe and device in biohazard waste.~3. Blue Cap the IV as per routine practice.
Study: NCT02088177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting injectable naltrexone
Description: Vivitrol is a long-acting opioid antagonist which blocks opioid agonists from binding at opioid receptors. It be administered as described above.
Study: NCT00795899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab
Description: Cycles 1-4 Epirubicin: 90 mg/m2, i.v. day 1 Cyclophosphamide: 600 mg/m2, i.v. day 1 Every 22d~Cycles 5-8 Paclitaxel: 175 mg/m2, i.v., 3h-infusion day 1 Trastuzumab: 8 mg/kg i.v. at day 0 of the 5th cycle and thereafter each 6 mg/kg i.v. day 1 in the cycles 6-8 Every 22d
Study: NCT04259671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: My Autism Passport (MAP) Application
Description: Families will be given the application to upload to their mobile device and will be provided information on how to use the App by the research team. MAP is a mobile alternative to the paper version, and offers additional benefits such as the ability to set reminders, see regional developmental service agencies and other resources on a map, and directs the caregiver to information so that they may further their understanding about how to support their child.
Study: NCT03123744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Palbociclib 125 mg is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study evaluations include physical exams, performance status, vital signs, laboratory blood tests, and radiographic or MRI imaging.
Study: NCT01766076

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: atorvastatin, Lipitor®
Description: PBMC collected for immune activation assays using flowcytometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: atorvastatin, Lipitor®
Description: PBMC collected for immune activation assays using flowcytometry
Study: NCT02303977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT03010475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral administration A total of three single doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral administration. A total of three single doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNAC
Description: Oral administration. A total of five single doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Oral administration. Once daily.
Study: NCT03500237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team-Guided ICBT
Description: An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will respond within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Guided ICBT
Description: An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no psychoeducational support will be provided. A team member from the Unit will contact the participant only if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms).
Study: NCT01901939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: daily tailored low level pedaling exercise at bedside
Study: NCT04688489

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbloading and maltodextrin
Description: The intervention is a dietary intervention that consists of a supplement of maltodextrin and added dietary carbohydrates. The supplement (20 g for women and 30 g for men) will be given to patients before and after a scheduled training, while the carbohydrates are given with meals. The extra carbohydrates given at meal time consists of extra potatoes, rice, bread, fruit, juice or other carbohydrate-rich food items.
Study: NCT03007615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intimate Lubricant Gel
Study: NCT03273257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.~Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given analogue to riociguat with matching tablets.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary endarterectomy
Description: PEA will be performed at the end of medical treatment (Day 90)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary endarterectomy
Description: PEA will be performed at the end of medical treatment (Day 90)
Study: NCT04216992

Intervention type: DEVICE
Intervention: Cone beam computed tomography
Description: The contrast agent (Omnipaque, GE Healthcare, Ireland) was instilled to conﬁrm the epidural space. With use of a calibrated angiographic C-arm system and a postprocessing workstation, we acquired volume data sets from two dimensional digital projection images obtained to reconstruct the 3D-RE during a C-arm rotation around the patient axis.
Study: NCT04723667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 13-week multimodal intervention
Description: The experimental intervention was a 13-week multimodal intervention consists of five-weekly, 90-minute, face-to-face sessions to be delivered in a group format (six to eight participants per group), followed by two weekly and three biweekly telephone follow-ups. The five face-to-face sessions covered brain health information, booster memory power, reducing stressors, optimizing strength and active lifestyle engagement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5-week health education programme
Description: The health education program consisted of three topics (fall prevention, oral care and home hygiene), with two tele-booster follow up
Study: NCT03252665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil
Description: alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: Nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitroglycerin
Description: Nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
Study: NCT04706494

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AlphaWave® LTheanine
Description: 200 mg of AlphaWave® LTheanine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose
Study: NCT03908840

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI 302
Description: TBI 302 administered once a week in first 3 weeks and no treatment in week 4 (28 days is 1 cycle). Followed once weekly treatment of TBI 302 for 3 weeks followed by no treatment in week 4 (cycle 2)
Study: NCT03055286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CWP232291
Description: For cohort 1-3, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 5 following CWP232291 infusion.~For cohort 4, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 7 following 250 mg/m2 CWP232291 infusion.
Study: NCT01173380

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soy nuts
Description: Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Matched food
Description: Control food (matched for calories and macronutrients) per day for 4 weeks
Study: NCT00625313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HMY Model YA-60BB IOL
Description: Following phacoemulsification cataract extraction, insertion of a Hoya HMY posterior chamber intraocular lens will be performed.
Study: NCT03107715

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding Champion
Description: iPad-based behavioral intervention facilitated by researcher

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Messaging
Description: iPad based behavioral intervention facilitated by researcher
Study: NCT03305159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Patients will receive povidone iodine for the surgical preparation of the vagina.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Chlorhexidine Gluconate
Description: Patients will receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
Study: NCT03079739

Intervention type: DIAGNOSTIC_TEST
Intervention: fractional flow reserve
Description: assessment with FFR in at least one coronary lesion
Study: NCT00506558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventral Surgical Decompression with Instrumented Fusion
Description: Multi-level discectomy or Corpectomy are performed at surgeon's discretion. After decompression an instrumented fusion is performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal Decompression With or Without Fusion
Description: Dorsal decompressive laminectomy, laminoplasty, or laminectomy with lateral mass instrumented fusion
Study: NCT00470249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: At a dose equivalent to an area under the concentration-time curve of 4.5 mg/ml.min on day 1 of every 2-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: 1500 mg/m2 on day 2 of every 2-week cycle
Study: NCT03504839

Intervention type: DEVICE
Group type: OTHER
Intervention: Subcutaneous ICD with same day discharge
Description: Receiving a SICD and discharged the same day
Study: NCT00985127

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administered daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Administered daily for 21 days.
Study: NCT03945929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction
Description: Distraction-1 Group: Cards containing approximately six optical illusion pictures were shown to the patients and as a method of distraction during the PIC insertion procedure they were asked what they saw in these cards.~Distraction-2 Group: Underwater 3D audial videos were played with visual reality (VR) goggles during PIC insertion until the procedure was completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction
Description: Distraction-1 Group: Cards containing approximately six optical illusion pictures were shown to the patients and as a method of distraction during the PIC insertion procedure they were asked what they saw in these cards.~Distraction-2 Group: Underwater 3D audial videos were played with visual reality (VR) goggles during PIC insertion until the procedure was completed.
Study: NCT02048059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG1005
Study: NCT02494804

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CIK
Description: The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
Study: NCT02831686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT02831478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Applied liberally to the skin (Formulation: RB# Z16-071)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen Lotion (RB# T78-190B)
Description: Applied liberally to the skin
Study: NCT04368117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Directed and prescribe physical therapy program for severely burned patients

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Directed and prescribe physical therapy program for severely burned patients
Study: NCT01898884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP 20629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP 20629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01766076

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PBMC collected for immune activation assays using flowcytometry
Study: NCT04607408

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, 0.9% USP
Study: NCT03393611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Salvage Chemotherapy: CPX-351 at 120 u/m2 on Days -21, -19, and -17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 150 mg/m2 (30 mg/m2/day x 5 days, Day -7 to Day -3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 140 mg/m2 (Day -2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Anti-Human T-Lymphocyte Globulin
Description: Rabbit ATG (rATG)-thymoglobulin 4.5 mg/kg (1.5 mg/kg/day x 3 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haplo-Cord Stem Cell Transplantation
Description: Allogeneic stem cell transplantation using a haploidentical donor and umbilical cord blood unit.
Study: NCT00822601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Arm 1 (experimental) : rTMS, 4 weeks of stimulation with RMT frequency 1Hz, intensity 100% of RMT for 20 minutes (1500 pulses), 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Comparator
Description: sham rTMS (using a placebo coil), 4 weeks of stimulation, will mimic the active treatment mentioned above.
Study: NCT01766076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PBMC collected for immune activation assays using flowcytometry
Study: NCT02350023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical latanoprost 0.005%
Description: Local application of the drug on affected skin/scalp

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical betamethasone 0.05%
Description: Local application of the drug on affected skin/scalp
Study: NCT00380874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150- 600 mg/day (double blind in divided doses)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03164551

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GERI+ incubator
Description: The embryo culture of consented participants were carried out in GERI+ incubator for both bright-field and dark-field time lapse monitoring until Day 3 of embryo culture. On Day 3, all embryos were reviewed firstly by GERI Assess software, using bright-field imaging. Finally the embryo(s) with the highest EEVA grade are transferred were followed up until the achievement of implantation and confirmation of pregnancy.

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional incubator
Description: The embryo culture of consented participants were carried out in conventional incubator for culture until Day 3 of embryo culture. On Day 3 of embryo culture, all embryos are assessed using a bench-top microscope. The embryo(s) with optimal cell stage and grade were transferred and were followed up until the achievement of implantation and confirmation of pregnancy.
Study: NCT01987778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training supervised and individualized by an experienced physiotherapist. First the relative load will be lighter during three weeks, thereafter the intensity and load will be increased over another 12 weeks.
Study: NCT02462603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC-589
Description: PTC-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.
Study: NCT01475799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Replacement of the Aortic Stenotic Valve
Description: Treatment for patients with Severe Aortic Stenosis.
Study: NCT01435850

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: primary total hip arthroplasty
Description: All patients eligible to the study criteria will be included. A total hip arthroplasty unilateral will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary total hip arthroplasty
Description: All patients eligible to the study criteria will be included. A total hip arthroplasty unilateral will be performed.